Lenzilumab ELISA Kit (DY213018)

Overview

Catalog No.	DY213018
Sample type	Plasma, Serum
Sensitivity	0.156 μg/ml
Range	0.31-5 μg/mL
Accession	P04141
Applications	ELISA
Detection method	Colorimetric
Assay type	Quantitative
Recovery	80-120%
Shipping	2-8 ℃
Stability and Storage	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Specifications	Lenzilumab
Alternate Names	KB-003, 1229575-09-0
Background	Lenzilumab is a novel Humaneered ® anti-human GM-CSF monoclonal antibody that directly binds GM-CSF and prevents signaling through its receptor. The LIVE-AIR Phase 3 randomized, double-blind, placebo-controlled trial investigated the efficacy and safety of lenzilumab to assess the potential for lenzilumab to improve the likelihood of ventilator-free survival (referred to herein as survival without ventilation, SWOV), beyond standard supportive care, in hospitalized subjects with severe COVID-19.
Note	For Research Use Only.

Images

References

Datasheet